JPRN-UMIN000000916已完成未知
Randomized study of docetaxel or weekly paclitaxel followed by 5FU + epirubicin + cyclophosphamide as preoperative chemotherapy for primary breast cancer - Randomized study of docetaxel or weekly paclitaxel followed by 5FU + epirubicin + cyclophosphamide as preoperative chemotherapy for primary breast cancer(KBCOG-06)
kobe breast cancer oncology group0 个研究点目标入组 50 人开始时间: 2007年12月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) severe comorbidity 2) alergy to polysorbate 80 3) alergy to clemohol EL 4) active infection 5) severe peripheral neuropathy 6) alcohol intolerance 7) pregnant or lactating women
研究者
相似试验
已完成
2 期
A Randomized phase II study of docetaxel versus weekly carboplatin and CPT-11 for previously treated Non-Small cell lung cancerJPRN-C000000147West Japan Oncology Group64
招募中
不适用
Phase I/II study of bi-weekly docetaxel and cisplatin plus S-1 (bi-weekly DCS) as first-line therapy for advanced esophageal cancer.Esophageal cancerJPRN-UMIN000032257The University of Tokyo50
招募中
1 期
Phase I/II study of bi-weekly DCS as first-line therapy for advanced esophageal cancer.Esophageal cancerJPRN-jRCTs031180376Seto Yasuyuki38
进行中（未招募）
不适用
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - DOCOX GASTRIC (Docetaxel-Oxaliplatin in Gastric Cancer)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-HUSanofi-aventis groupe270
进行中（未招募）
不适用
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - GATE (GAstric cancer study with Taxotere-Eloxatin-based regimens)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-BESanofi-aventis groupe270